References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
See detailEstablished postmenopausal osteoporosis – Assessment of treatment options
Reginster, Jean-Yves ULg; Halkin, V.; Fraikin, G. et al

in Menopause Review (1999), 1(IV), 39-55

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailProphylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis
Reginster, Jean-Yves ULg; Kuntz, D.; Verdickt, W. et al

in Osteoporosis International (1999), 9(1), 75-81

One hundred and forty-five patients suffering from diseases requiring long-term treatment with high doses of corticosteroids (30 mg/day or greater of prednisolone) were recruited to the study. Patients ... [more ▼]

One hundred and forty-five patients suffering from diseases requiring long-term treatment with high doses of corticosteroids (30 mg/day or greater of prednisolone) were recruited to the study. Patients had to be steroid naive on entry to the study (not more than 15 days of treatment with a corticosteroid within the previous 24 months). Patients were randomized to receive either 1 microgram/day alfacalcidol or placebo capsules for 12 months. Bone mineral density (BMD) of the lumbar spine was assessed by dual-photon absorptiometry on entry and after 3, 6 and 12 months' treatment. Safety was monitored by the recording of all adverse events reported by patients and the regular screening of blood samples for hematology and serum biochemistry. Of the 145 patients, 74 were randomized to alfacalcidol and 71 to placebo. The treatment groups were well matched at baseline with no significant differences in demographic, clinical or biochemical parameters. The mean equivalent dose of prednisolone at baseline was 46.6 mg/day and 46.3 mg/day for the alfacalcidol and placebo group respectively. From the 145 patients randomized to treatment, 71 (38 who received alfacalcidol and 33 who received placebo) provided BMD data both at baseline and at 3, 6 and 12 months. The percentage change in BMD after 6 months' treatment was -2.11% in the alfacalcidol group and -4.00% in the placebo group (p = 0.39). After 12 months the percentage change in BMD was +0.39% (CI: -4.28 to 4.81) in the alfacalcidol group and -5.67% (CI: -8.13 to -3.21) in the placebo group, this difference (6.06%, CI: 0.88 to 11.24) being statistically significant (p = 0.02). An intention to treat analysis also showed a significant difference between the two treatment groups in alfacalcidol's favor (3.81%, p = 0.01; CI: 0.92 to 6.70). There was no significant difference between the two treatment groups in the corticosteroid dose at any time point during the study. Serum calcium was measured throughout and there were no significant differences between the two treatment groups at any visit. This study suggests that alfacalcidol can prevent corticosteroid-induced bone loss from the lumbar spine. Long-term use of alfacalcidol was not associated with any significant adverse effects in this diverse group of patients. [less ▲]

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of Osteoporosis: Role of Bone-Forming Agents
Reginster, Jean-Yves ULg; Halkin, V.; Henrotin, Yves ULg et al

in Osteoporosis International (1999), 9 Suppl 2

Detailed reference viewed: 3 (1 ULg)
See detailGonarthrose: intérêt de l'évaluation isocinétique
Croisier, Jean-Louis ULg; Henrotin, Yves ULg; Dumont, R. et al

in KINE 2000 (1998, December), 9(98/5), 90

Detailed reference viewed: 39 (1 ULg)
Peer Reviewed
See detailMorphometric Study of the Equine Navicular Bone: Variations with Breeds and Types of Horse and Influence of Exercise
Gabriel, Annick ULg; Jolly, Sandra ULg; Detilleux, Johann ULg et al

in Journal of Anatomy (1998), 193((Pt 4)), 535-49

Navicular bones from the 4 limbs of 95 horses, classified in 9 categories, were studied. The anatomical bases were established for the morphometry of the navicular bone and its variations according to the ... [more ▼]

Navicular bones from the 4 limbs of 95 horses, classified in 9 categories, were studied. The anatomical bases were established for the morphometry of the navicular bone and its variations according to the category of horse, after corrections were made for front or rear limb, sex, weight, size and age. In ponies, navicular bone measurements were smallest for light ponies and regularly increased with body size, but in horses, navicular bone dimensions were smallest for the athletic halfbred, intermediate for draft horse, thoroughbreds and sedentary halfbreds and largest for heavy halfbreds. The athletic halfbred thus showed reduced bone dimensions when compared with other horse types. Navicular bones from 61 horses were studied histomorphometrically. Light horses and ponies possessed larger amounts of cancellous bone and less cortical bone. Draft horses and heavy ponies showed marked thickening of cortical bone with minimum intracortical porosity, and a decrease in marrow spaces associated with more trabecular bone. Two distinct zones were observed for the flexor surface cortex: an external zone composed mainly of poorly remodelled lamellar bone, disposed in a distoproximal oblique direction, and an internal zone composed mainly of secondary bone, with a lateromedial direction for haversian canals. Flexor cortex external zone tended to be smaller for heavy ponies than for the light ponies. It was the opposite for horses, with the largest amount of external zone registered for draft horses. In athletic horses, we observed an increase in the amount of cortical bone at the expense of cancellous bone which could be the result of reduced resorption and increased formation at the corticoendosteal junction. Cancellous bone was reduced for the athletic horses but the number of trabeculae and their specific surfaces were larger. Increased bone formation and reduced resorption could also account for these differences. [less ▲]

Detailed reference viewed: 44 (8 ULg)
Full Text
Peer Reviewed
See detailEfficacy and Tolerability of Calcitonin in the Prevention and Treatment of Osteoporosis
Halkin, V; Reginster, Jean-Yves ULg

in BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals & Gene Therapy (1998), 10(4), 295-300

Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic ... [more ▼]

Calcitonin in general, and, more specifically, salmon calcitonin (salcatonin), has been known for 30 years to be a specific inhibitor of bone resorption. Studies have confirmed its efficacy in metabolic bone diseases characterised by excessive bone resorption, such as osteoporosis. Most randomised studies in which salcatonin and oral calcium were administered for 1 to 5 years to recently postmenopausal women for the prevention of osteoporosis have shown that bone mineral density or bone content of the lumbar spine increased significantly, compared with a reduction among women receiving calcium only. Prospective studies have shown that salcatonin is effective in the treatment of established osteoporosis, reducing significantly the relative risk of new vertebral fractures. The benefits of salcatonin nasal spray therapy were observed in the majority of women studied, and it has been shown to be an effective alternative for osteoporotic women more than 5 years postmenopausal who refuse estrogens, or for whom estrogens are contraindicated. Finally, in established osteoporosis, nasal calcitonin possesses a potent analgesic effect. The well-demonstrated effects of nasal calcitonin permit it to be considered a well tolerated and efficient approach for prevention and treatment of postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 6 (4 ULg)
Full Text
Peer Reviewed
See detailNitric Oxide Downregulates Interleukin 1β (IL-1β) Stimulated IL-6, IL-8, and Prostaglandin E2 Production by Human Chondrocytes
Henrotin, Yves ULg; Zheng, S. X.; Deby, G. P. et al

in Journal of Rheumatology (1998), 25(8), 1595-601

OBJECTIVE: To investigate the effects of endogenously produced nitric oxide (NO) on interleukin 6 (IL-6), IL-8, prostaglandin E2 (PGE2), and proteoglycan production by human chondrocytes. METHODS: Human ... [more ▼]

OBJECTIVE: To investigate the effects of endogenously produced nitric oxide (NO) on interleukin 6 (IL-6), IL-8, prostaglandin E2 (PGE2), and proteoglycan production by human chondrocytes. METHODS: Human articular chondrocytes were isolated from their extracellular matrix by triple successive enzymatic digestion of the cartilage and cultured 48 h in a well defined culture medium. IL-6 and IL-8 were directly assayed into culture media by specific enzyme amplified sensitivity immunoassays. Proteoglycans and PGE2 were quantified by specific radioimmunoassays. Cell culture media were assayed for NO2 using a spectrophotometric assay based upon the Griess reaction. RESULTS: Unstimulated chondrocytes produced low levels of NO, IL-6, IL-8, and PGE2. Production was significantly stimulated by IL-1beta and lipopolysaccharide (LPS). As well, proteoglycan synthesis was profoundly inhibited by IL-1beta and LPS. Inhibition of NO synthesis with the competitive inhibitor NG-monomethyl-L-arginine (L-NMMA) led to enhancement of IL-6, IL-8, and PGE2 production stimulated by either IL-1beta alone or in combination with LPS, whereas the inhibition of proteoglycan production by IL-1beta was not modified by L-NMMA. CONCLUSION: LPS and IL-1beta stimulated IL-6, IL-8, and PGE2 production are downregulated by endogenously produced NO, which could limit the inflammatory reaction occurring in arthritis. [less ▲]

Detailed reference viewed: 19 (8 ULg)
Full Text
Peer Reviewed
See detailThe Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial
Reginster, Jean-Yves ULg; Meurmans, L.; Zegels, Brigitte ULg et al

in Annals of Internal Medicine (1998), 129(1), 1-8

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are ... [more ▼]

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are controversial. OBJECTIVE: To study the effect of low-dose fluoride (sodium monofluorophosphate [MFP]) plus a calcium supplement over 4 years on vertebral fractures and BMD at the lumbar spine and total hip in postmenopausal women with moderately low BMD of the spine. DESIGN: Randomized, double-blind, controlled clinical trial. SETTING: Outpatient clinic for osteoporosis at a university medical center. PATIENTS: 200 postmenopausal women with osteoporosis (according to the World Health Organization definition) and a T-score less than -2.5 for BMD of the spine. INTERVENTION: Women were randomly assigned (100 patients per group) to continuous daily treatment for 4 years with 1) oral MFP (20 mg of equivalent fluoride) plus 1000 mg of calcium (as calcium carbonate) or 2) calcium only. MEASUREMENTS: Lateral spine radiographs were taken at enrollment and at each year of follow-up for detection of new vertebral fractures (defined as a reduction > or =20% and > or =4 mm from baseline in any of the heights of a vertebral body). Nonvertebral fractures were also recorded. All analyses were done with the intention-to-treat approach. RESULTS: Radiologic follow-up was possible for 164 of 200 patients (82%). The rate of new vertebral fractures during the 4 years of the study was lower in the MFP-plus-calcium group (2 of 84 patients; 2.4% [95% CI, 0.3% to 8.3%]) than in the calcium-only group (8 of 80 patients; 10% [CI, 4.4% to 18.8%]). The difference between the groups was 7.6 percentage points (CI, 0.3 to 15 percentage points) (P = 0.05). A moderate but progressive increase in BMD of the spine (10.0% +/- 1.5% at 4 years) was found for MFP plus calcium compared with calcium only (P < 0.001), whereas the more modest increase in BMD of the total hip seen with MFP plus calcium (1.8% +/- 0.6%) did not differ from the increase seen with calcium only. CONCLUSIONS: Low-dose fluoride (20 mg/d) given continuously with calcium for prolonged periods can decrease vertebral fracture rates compared with calcium alone in patients with mild to moderate osteoporosis. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailTherapy for Osteoporosis. Miscellaneous and Experimental Agents
Reginster, Jean-Yves ULg; Taquet, A. N.; Gosset, Christiane ULg

in Endocrinology & Metabolism Clinics of North America (1998), 27(2), 453-63

None of the currently available medications for osteoporosis have demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is ... [more ▼]

None of the currently available medications for osteoporosis have demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is established. Several new therapies, therefore, are currently being developed to optimize the risk/benefit ratio of osteoporosis treatment. This article discusses a number of treatments currently being considered, including anabolic steroids, growth hormone or insulin-like growth factors, ipriflavone, parathyroid peptides, and strontium. Several other compounds have been suggested recently for treatment of osteoporosis and other are at very early stages of their development. In addition to pharmacologic approaches to the treatment of osteoporosis, hip protectors also may reduce hip fractures. [less ▲]

Detailed reference viewed: 8 (3 ULg)
Peer Reviewed
See detailComputerised method to measure asymetrical articular compression on digitised X-rays
Caudron, I; Henrotin, Yves ULg; Reginster, Jean-Yves ULg et al

in Rivista SIDI Proceedings 5th WEVA Congress (1st part) (1998)

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailReproducibility and diagnostic sensitivity of ultrasonometry of the phalanges to assess osteoporosis.
Reginster, Jean-Yves ULg; Dethor, M; Pirenne, H et al

in International Journal of Gynecology & Obstetrics (1998), 63(1), 21-8

OBJECTIVE: The present study was designed to assess the reproducibility and the diagnostic sensitivity of the amplitude-dependent speed of sound (SoS) at the distal metaphysis of the proximal phalanges ... [more ▼]

OBJECTIVE: The present study was designed to assess the reproducibility and the diagnostic sensitivity of the amplitude-dependent speed of sound (SoS) at the distal metaphysis of the proximal phalanges. METHOD: Fourteen presumably healthy volunteers were repeatedly measured every 6 weeks for approximately 6 months in order to assess the reproducibility of the SoS of the phalanges. We recruited 91 post-menopausal women, aged 55-75 years, who were divided in three groups according to their lumbar bone mineral density (BMD) and the existence of prevalent vertebral fractures. The objective was to evaluate the diagnostic sensitivity of SoS measurements. We used DBM Sonic 1200 equipment, and assessed the velocity at which US cross the phalanx in a lateral-medial direction. In post-menopausal women, BMD was measured by dual energy X-ray absorptiometry (DXA) at the level of the lumbar spine, the total zone of the non-dominant hip and the femoral neck zone of the non-dominant hip. RESULTS: The precision of the SoS measurements was 0.71+/-0.05% (mean+/-S.E.M) whereas the reproducibility was 0.95+/-0.06%. Subjects with low BMD or prevalent fractures had significantly lower values of SoS (P < 0.001) than the controls. ROC curve analysis applied to the study population confirmed that SoS was able to discriminate between the controls and osteoporotic subjects (area under the ROC curves were 0.82 (low bone mineral density) and 0.85 (prevalent fractures), respectively). Hip BMD was found to be the most significant variable when comparing the controls and the low density patients by stepwise discrimination and SoS significantly improved the discrimination between the groups when added to the hip BMD. The hip BMD was again the most discriminant variable when applying the same techniques to controls and patients with prevalent fractures, followed by SoS and lumbar BMD. A cut-off value of 1881 m/s is defined for SoS by logistic discrimination and likelihood ratio function. With this value, the sensitivity and the specificity for SoS used in the diagnosis of established osteoporosis were, 81.5% and 79.3%, respectively. Sensitivity and specificity were significantly improved when combining ultrasonometry and densitometry. CONCLUSION: Measurement of ultrasound velocity at the phalanges appears to be a precise and reproducible technique. SoS discriminates between normal post-menopausal women and patients with either low lumbar BMD or prevalent fractures to the same extent as BMD measurements. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailLes thérapeutiques à visée spécifiquement osseuse dans le traitement de l'ostéoporose postménopausique. Aspects pharmaco-économiques
Reginster, Jean-Yves ULg; Ben Sedrine, Wafa ULg; Gosset, Christiane ULg

in Revue Médicale de Liège (1998), 53(5), 290-293

Fairly new economic evaluations were, so far, properly conducted in the field of prevention and treatment of osteoporosis. This lack of studies is likely to be related to the pathophysiology and the ... [more ▼]

Fairly new economic evaluations were, so far, properly conducted in the field of prevention and treatment of osteoporosis. This lack of studies is likely to be related to the pathophysiology and the natural course of the disease, the small number of disease-specific instruments allowing the evaluation of quality of life changes following fractures and the frequent interaction of osteoporotic treatments with other body systems. Notwithstanding a lot of efforts have to be brought before economic evaluations in osteoporosis become a key determinant of Public Health strategies, it remains of prime interest to promote this type of research taking into account the importance of the social, human and economic burden of this disease. [less ▲]

Detailed reference viewed: 35 (17 ULg)
Peer Reviewed
See detailIn vitro models for the study of cartilage damage and repair
Henrotin, Yves ULg; Labasse, A; Zheng, SX et al

in Rheumatology in Europe (1998), 27(S2), 7

Detailed reference viewed: 10 (3 ULg)
Peer Reviewed
See detailL’INF gamma est un inhibiteur puissant de la synthèse d’IL-8 par les chondrocytes humains
Henrotin, Yves ULg; Zheng, SX; Deby, G et al

in Revue du Rhumatisme (1998), 11

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailEffets du monoxyde d’azote (NO) sur le métabolisme des chondrocytes
Henrotin, Yves ULg; Zheng, SX; Deby, G et al

in Revue du Rhumatisme (1998), 11

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailIFN gamma inhibits IL-8 production by IL-1bêta and TNFalpha stimulated human chondrocytes
Henrotin, Yves ULg; Zheng, SX; Deby, G et al

in Revue du Rhumatisme (English ed.) (1998), 11

Detailed reference viewed: 7 (0 ULg)
Peer Reviewed
See detailNitric oxid (NO) down-regulates cytokines and PGE2 production by human chondrocytes
Henrotin, Yves ULg; Zheng, SX; Deby, G et al

in Revue du Rhumatisme (English ed.) (1998), 11

Detailed reference viewed: 8 (0 ULg)
Peer Reviewed
See detailWhich test for which patient ?
Reginster, Jean-Yves ULg

in Osteoporosis International (1998), 8(S3), 152

Detailed reference viewed: 4 (0 ULg)